To include your compound in the COVID-19 Resource Center, submit it here.

Blanket contracts in jeopardy

WASHINGTON - Controversy over the Scripps-Sandoz technology transfer agreement is likely to stimulate regulations to limit the scope and duration of collaborations between NIH grantees and private industry, according to an NIH official.

The Scripps Research Institute deal with Sandoz Pharmaceuticals Corp. violates the intent of federal technology transfer policy but

Read the full 507 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE